

The use of adipose derived stem cells in degenerative diseases

Kristin Comella

Ageless Regenerative Institute and Bioheart, USA

This presentation will review cellular science and the role of stem cells in clinical practice. Adipose derived stem cells (ADSCs) include mesenchymal stem cells, which have adipogenic, myogenic, and chondrogenic potential and are very angiogenic in nature. This population of cells also includes hematopoietic stem cells, pericytes, and endothelial progenitor cells. ADSCs are multipotential cells that can be utilized in regenerating diseased or damaged tissue throughout the body. This talk will educate physicians to understand how to critically assess cell yields, cell characterization, and viability so they can interpret claims made by different technologies. Understanding the science of stem cells can help physicians identify the appropriate patient population and clinical indications. In addition, results from clinical trials in congestive heart failure and chronic obstructive pulmonary disease will be presented.

Biography

Ms. Comella has over 12 years experience in corporate entities with expertise in regenerative medicine, training and education, research, product development, and senior management. Ms. Comella has been a member of the Bioheart Inc. senior management team since 2004 and is currently serving as the Chief Scientific Officer. Bioheart is a publically traded company focusing on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Ms. Comella was appointed as Bioheart's Vice President of R&D and Corporate Development in December 2008. Since joining Bioheart in September 2004, she has played a major role in managing the product development, manufacturing and quality systems.

kcomella@agelessregen.com